{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.44","upperLimit":"9.3","value":"5.59"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Combined Safety Lead-in"}],"paramType":"MEDIAN","populationDescription":"The SLI Efficacy Set consisted of all CSLI participants in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).","reportingStatus":"POSTED","timeFrame":"From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 280 weeks)","title":"(Safety Lead-in) Progression-Free Survival (PFS) by BICR","type":"SECONDARY","unitOfMeasure":"Months"}